Wade Iams Kathyrn Eby Beckermann Anne T Neff Ingrid A Mayer Vandana Gupta Abramson
10.1007/s12032-013-0568-x
Med Oncol
2013;30(2):568.
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/23564368/
Antineoplastic Combined Chemotherapy Protocols / adverse effects Antineoplastic Combined Chemotherapy Protocols / therapeutic use Breast Neoplasms / blood Breast Neoplasms / drug therapy Thrombotic Microangiopathies / chemically induced
Antineoplastic Combined Chemotherapy Protocols / adverse effects Antineoplastic Combined Chemotherapy Protocols / therapeutic use Breast Neoplasms / blood Breast Neoplasms / drug therapy Thrombotic Microangiopathies / chemically induced Case Reports Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects Carboplatin / administration & dosage Carboplatin / adverse effects Chemotherapy, Adjuvant Docetaxel Female Humans Middle Aged Receptor, ErbB-2 / biosynthesis Taxoids / administration & dosage Taxoids / adverse effects Trastuzumab Antibodies, Monoclonal, Humanized Taxoids Docetaxel Carboplatin Receptor, ErbB-2 Trastuzumab
PMC3774143
23564368
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case report
2013